Jump to content

new here - anyone know anything about Bevacizumab?

Guest daddysgirl

Recommended Posts

Guest daddysgirl

Hey guys, my name is Ashley...I just found out 2 weeks ago that my father has lung cancer..now today I found out that a small tumor is on his shoulder. I am dying inside knowing what he is going to have to go through. The doctors would like him to do the experimental drug thing, its called Bevacizumab. Can anyone give me info on how it has affected other peopl doing this trial?? Thanks

Link to comment
Share on other sites

Welcome Ashley, From what I have just read it seems like it works fairly well when combined with chemo. It seems to have an increased rate of serious side effects when compared to basic standard chemo. But in my opinion preventing angiogenesis is crucial in stopping the cancer from growing, once chemo has shrunk it. There are a lot of less toxic ways of doing the same thing as bevacizumab, but it is a good start.

Best of Luck,


Targeting VEGF

In lung cancer, the largest clinical experience has been reported for bevacizumab, an anti-VEGF antibody. Phase 1 trials have demonstrated its safety and, because of the long half-life observed, weekly intravenous doses of 5-15 mg/kg were recommended for further study. A randomized phase 2 trial that evaluated the combination of paclitaxel/carboplatin alone or with bevacizumab at either 5 mg/kg or 15 mg/kg was conducted.[12,13]

The objective response rates were higher in the 2 groups receiving bevacizumab, whether the response was scored by the investigator or by an independent review panel. Time to progression (TTP) was longer in the bevacizumab groups, with the longest TTP in the high-dose group. Survival was also longest in the high-dose bevacizumab group, but it was longer than expected from historical controls in all groups. This might be attributed to the fact that the patients in the chemotherapy-alone group were allowed to cross over to receive antibody at the time of progression.

The study was complicated by the unexpected development of a severe, and occasionally lethal toxicity, pulmonary hemorrhage. There were 6 deaths from this complication in the bevacizumab-treated groups, but none in the chemotherapy-alone group. This complication was more frequent in patients with central tumors, especially tumors of squamous cell histology. The results of this trial led the Eastern Cooperative Oncology Group (ECOG) to institute a randomized phase 3 trial comparing paclitaxel/carboplatin alone with paclitaxel/carboplatin plus high-dose bevacizumab. This trial is currently in progress.

Unexpected bleeding problems have also been observed with several small VEGF receptor-directed TKIs. Clinical trials with one of these agents, SU5461, were discontinued due to lack of efficacy, but phase 1 and phase 2 clinical trials with most of the other agents listed above are continued

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.